drugset / Trial / NCT01470118

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

NCT01470118

Phase 4 Completed 127 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.

Timeline

Start
2011-10
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alcaftadine Small molecule 0.25 % Other
Comparator Olopatadine Other / unclassified 0.2 % Other

Indications